Despite the significant public health issue that it poses, only five medical treatments have
been approved for Alzheimer's disease (AD) and these act to control symptoms rather than …

The past decade has seen the convergence of a series of new insights that arose from
genetic and systems analyses of Alzheimer's disease (AD) with a wealth of epidemiological …

Current Alzheimer's disease (AD) diagnostics is based on clinical assessments, imaging
and neuropsychological tests that are efficient only at advanced stages of the disease. Early …

Alzheimer's disease (AD), including its mild cognitive impairment (MCI) phase that may or
may not progress into the AD, is the most ordinary form of dementia. It is extremely important …

Almost a quarter of a century ago, interleukin-6 (IL-6) was discovered as an inflammatory
cytokine involved in B cell differentiation. Today, IL-6 is recognized to be a highly versatile …

Background Despite decades of intensive research, to date, there is no accepted diagnosis
for Parkinson's disease (PD) based on biochemical analysis of blood or CSF. However …

Intranasal insulin (INI) has shown promise as a treatment for Alzheimer's disease (AD) in
pilot clinical trials. In a recent phase 2 trial, participants with mild cognitive impairment (MCI) …

The feasibility of assaying plasma phosphorylated tau protein (threonine 181), denoted p-
tau181, using immunomagnetic reduction (IMR) is explored. The reagent for assaying p …

Amnestic mild cognitive impairment (aMCI) often is an early stage of Alzheimer's disease
(AD). MCI is characterized by cognitive decline departing from normal cognitive aging but …

Background: Current research criteria for Alzheimer's disease (AD) include cerebrospinal
fluid (CSF) biomarkers into the diagnostic algorithm. However, spreading their use to the …